Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

International conference on breaking cycles of the past in societies affected by historical trauma presented from 5-8 December 2012
2012-11-28

Marguerite Barankitse from Burundi
28 November 2012

An interdisciplinary group of scholars, experts and practitioners from 24 countries around the world will gather at the University of the Free State (UFS) in Bloemfontein from 5 - 8 December 2012 for a conference on “Engaging the Other: Breaking Intergenerational Cycles of Repetition.”

The conference intends to open new avenues of inquiry into the trans-generational effects of trauma on communities that have experienced extreme violence.

One of the highlights of the conference is a presentation by Marguerite Barankitse, a survivor of the Rwandan genocide, on Thursday 6 December 2012. Marguerite has received several awards and distinctions for her work aimed at transforming the lives of Hutu and Tutsi children affected by war. Among these are the highly prestigious humanitarian prize, the Opus Prize, the UNESCO Prize, and the World's Children's Prize, also known as the ‘Nobel Prize’ for humanitarian work aimed at improving the lives of children and their chances of a better future.

On Saturday 8 December 2012 Prof. Martha Nussbaum, one of the world’s foremost philosophers, will deliver a keynote address on “Reconciliation: The political role of the Arts.” Prof. Nussbaum will receive a D.Litt. degree in the Faculty of Humanities from the UFS on 6 December 2012.

Other guests include Michael Lapsley, survivor of an apartheid bombing, Kimberlyn Leary, Associate Professor at Harvard Medical School,  Dr Jean Decety, Irving B. Harris Professor at the University of Chicago and Dr Katerina Fotopoulou from the Institute of Cognitive Neuroscience at the University College in London.

One of the conference events entitled “South Africans speak about the crisis of moral leadership: A public dialogue” will be open to the public and presented in the Centenary Complex on Friday 7 December 2012 from 18:00-19:30. Participants in the public dialogue include some of South Africa’s most thoughtful social commentators and a community activist: Barney Pityana (Professor and Rector, College of Transfiguration); Prince Mashele (Director: Centre for Politics and Research); Pierre de Vos (Professor of Law, University of Cape Town); and Faeza Meyer (Chairperson: Tafelsig Residents Unite).

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept